Assembly Biosciences (ASMB) CMO awarded 14,000 restricted stock units

Rhea-AI Filing Summary

White Nicole S reported acquisition or exercise transactions in this Form 4 filing.

Assembly Biosciences reported that Chief Manufacturing Officer Nicole S. White received a grant of 14,000 shares of common stock in the form of restricted stock units as part of her annual equity compensation. The RSUs were approved on March 29, 2026 and became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026.

The RSUs vest in four approximately equal installments on March 29 of 2027, 2028, 2029, and 2030, assuming she remains in continuous service. Following this grant and an administrative correction that removed 3,332 shares from prior totals, she now directly holds 48,145 shares of common stock.

Insider Trade Summary

Net Buyer: 14,000 shares

Net Buy 1 txn

Insider White Nicole S

Role Chief Manufacturing Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	14,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 48,145 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026 and was contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increased the number of shares of common stock authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted on March 29, 2026, the RSUs became issuable upon stockholder approval of the Plan Amendment on June 4, 2026 and vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030.
2. F2. Reflects 3,332 fewer shares included in in Column 5 on reporting person's prior Form 4s due to an administrative error.

Key Figures

RSU grant size: 14,000 shares Grant price: $0.0000 per share Post-grant holdings: 48,145 shares +2 more

5 metrics

RSU grant size 14,000 shares Restricted stock units granted March 29, 2026

Grant price $0.0000 per share RSU grant to Chief Manufacturing Officer

Post-grant holdings 48,145 shares Common stock directly held after transaction

Share count correction 3,332 shares Fewer shares now reflected due to administrative error

Plan approval date June 4, 2026 Stockholders approved Plan Amendment enabling RSU issuance

Key Terms

Restricted stock units ("RSUs"), annual equity grant, Amended and Restated 2018 Stock Incentive Plan, Plan Amendment, +1 more

5 terms

Restricted stock units ("RSUs") financial

"Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

annual equity grant financial

"RSUs representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026"

Amended and Restated 2018 Stock Incentive Plan financial

"an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan")"

Plan Amendment regulatory

"authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted"

administrative error other

"Reflects 3,332 fewer shares included in in Column 5 on reporting person's prior Form 4s due to an administrative error."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/05/2026 - 05:11 PM Accepted by SEC EDGAR 06/05/2026 - 05:10 PM Learn about SEC filing dates

FAQ

What insider transaction did Assembly Biosciences (ASMB) report for Nicole S. White?

Assembly Biosciences reported that Chief Manufacturing Officer Nicole S. White received 14,000 restricted stock units as part of her annual equity grant. These RSUs are a stock-based compensation award rather than a market purchase and increase her direct common stock holdings to 48,145 shares.

How do the RSUs granted to ASMB’s Chief Manufacturing Officer vest over time?

The 14,000 RSUs granted to Assembly Biosciences’ Chief Manufacturing Officer vest in four approximately equal installments. Vesting dates are March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, and each installment requires her to remain in continuous service.

What stockholder approval was required for Nicole S. White’s RSU grant at ASMB?

The RSU grant was contingent on stockholder approval of an amendment to Assembly Biosciences’ Amended and Restated 2018 Stock Incentive Plan. The amendment increased shares authorized for issuance, and the RSUs became issuable only after stockholders approved this Plan Amendment on June 4, 2026.

How many Assembly Biosciences shares does Nicole S. White hold after the Form 4 transaction?

After the RSU grant became issuable and an administrative share-count correction, Nicole S. White directly holds 48,145 shares of Assembly Biosciences common stock. The filing also notes that 3,332 fewer shares are now reflected than on her prior Forms 4 due to the correction.

Did the Assembly Biosciences Form 4 disclose any share count correction for Nicole S. White?

Yes. The Form 4 notes that 3,332 fewer shares are now shown in Column 5 compared with Nicole S. White’s prior Forms 4. This change reflects an administrative error correction and does not represent a new market transaction or sale of shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

White Nicole S

(Last) (First) (Middle)

C/O ASSEMBLY BIOSCIENCES, INC.

TWO TOWER PLACE, 7TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Manufacturing Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/29/2026		A		14,000(1)	A	$0	48,145(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026 and was contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increased the number of shares of common stock authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted on March 29, 2026, the RSUs became issuable upon stockholder approval of the Plan Amendment on June 4, 2026 and vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030.

2. Reflects 3,332 fewer shares included in in Column 5 on reporting person's prior Form 4s due to an administrative error.

	/s/ John O. Gunderson, as Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)